IMforte: Transcriptomic analyses support lurbinectedin plus atezolizumab maintenance across molecular subtypes in ES-SCLC

CHICAGO 2026

Lung, Respiratory and Thoracic Cancer

IMforte: Superior quality-adjusted survival with lurbinectedin plus atezolizumab maintenance in treatment-naïve patients with ES-SCLC

ELCC 2026

Lung, Respiratory and Thoracic Cancer

IMpower133/IMbrella A: Long-term survival and molecular subtype analyses with first-line atezolizumab in extensive-stage SCLC

CHICAGO 2026

Lung, Respiratory and Thoracic Cancer

Jazz EMERGE 402: Final primary analysis supports real-world effectiveness of lurbinectedin in patients with previously treated ES-SCLC

Lung, Respiratory and Thoracic Cancer

Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19)

Eur J Cancer

Addeo A, Dietrich D, Mach N, Mark MT, Joerger M, Froesch P, Imbimbo M, König D, Fernandez E, Patzen A, Vees H, Picardi C, Früh M

doi: 10.1016/j.ejca.2025.116138

CHICAGO 2026

Breast Cancer

NATALEE: Gene expression analysis supports ribociclib plus NSAI across PAM50 intrinsic subtypes in HR-positive, HER2-negative early breast cancer

Lung, Respiratory and Thoracic Cancer

Lurbinectedin for extensive stage - small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes

Lung Cancer

Krayim B, Shalata W, Bar J, Moskovitz M, Rotem O, Urban D, Sorotsky HG, Kian W, Hanovich E, Marie R, Mann S, Gillis R, Basel A, Kornev G, Asna N, Peled N, Roisman LC

doi: 10.1016/j.lungcan.2025.108598

Non-Malignant Blood Disorders

Molecular Determinants of Thrombosis Recurrence Risk Across Venous Thromboembolism Subtypes

Blood

Munsch G, Thibord F, Bezerra OC, Brody JA, van Hylckama Vlieg A, Gourhant L, Chen MH, Samaria F, Germain M, Caro I, Suchon P, Olaso R, Wiggins KL, Saut N, Besse C, Goumidi L, Bacq D, Harrington LB, Boland A, Emmerich J, Smadja DM, Lemarie CA, Danckwardt S, Debette S, Deleuze JF, Jacqmin-Gadda H, Rodger MA, Gagnon F, Rosendaal FR, Johnson AD, Smith NL, Couturaud F, Morange PE, Tregouet DA

doi: 10.1182/blood.2024027879

Lung, Respiratory and Thoracic Cancer

Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZO

JTO Clin Res Rep

Falchero L, Amrane K, Godbert B, Leterre B, Madelaine J, Fournel P, Mascaux C, Raimbourg J, Schneider S, Swalduz A, Veillon R, Langlais A, Missy P, Morin F, Westeel V, Girard N

doi: 10.1016/j.jtocrr.2026.100964

Multiple Myeloma (MM)

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses

Blood Cancer J

Foster L, Anderson LD Jr, Chung A, Chaulagain CP, Pettijohn E, Cowan AJ, Costello C, Larson S, Sborov DW, Shain KH, Silbermann R, Voorhees P, Krevvata M, Pei H, Patel S, Khare V, Cortoos A, Carson R, Lin TS, Badros A

doi: 10.1038/s41408-025-01355-0

Related content

IMforte: Superior quality-adjusted survival with lurbinectedin plus atezolizumab maintenance in treatment-naïve patients with ES-SCLC

IMpower133/IMbrella A: Long-term survival and molecular subtype analyses with first-line atezolizumab in extensive-stage SCLC

Jazz EMERGE 402: Final primary analysis supports real-world effectiveness of lurbinectedin in patients with previously treated ES-SCLC

Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19)

NATALEE: Gene expression analysis supports ribociclib plus NSAI across PAM50 intrinsic subtypes in HR-positive, HER2-negative early breast cancer

Lurbinectedin for extensive stage - small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes

Molecular Determinants of Thrombosis Recurrence Risk Across Venous Thromboembolism Subtypes

Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZO

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses